PLAUR / CD87 Protein & Antibody (u-PAR, uPAR)

Plasminogen Activator, Urokinase Receptor / Cluster of Differentiation 87 (urokinase-type Plasminogen Activator Receptor)

PLAUR / CD87 Products

PLAUR / CD87 Protein, Recombinant

Molecule	Species	Description	Cat. No
PLAUR/CD87/u-PAR	Human	PLAUR/CD87/u-PAR Protein, Recombinant	10925-H08H
PLAUR/CD87/u-PAR	Mouse	PLAUR/CD87/u-PAR/Fc Protein, Recombinant	50160-M03H
PLAUR/CD87/u-PAR	Mouse	PLAUR/CD87/u-PAR Protein, Recombinant	50160-M08H

  10925-H08H: Immobilized human uPAR at 5 µg/ml (100 µl/well) can bind biotinylated human UPA with a linear ranger of 40-1000 ng/ml. Measured by its binding ability in a functional ELISA.

  50160-M03H: Immobilized human uPA at 5 µg/ml (100 µl/well) can bind mouse PLAUR with a linear ranger of 1.6-40 ng/ml. Measured by its binding ability in a functional ELISA.

PLAUR / CD87 Antibody

Molecule	Application	Description	Cat. No
Human PLAUR/CD87/u-PAR	WB, ELISA	PLAUR / CD87 / uPAR Antibody (Antigen Affinity Purified)	10925-RP02
Mouse PLAUR/CD87/u-PAR	WB, ELISA	Rabbit Polyclonal Antibody	50160-RP01
Mouse PLAUR/CD87/u-PAR	WB, ELISA	Rabbit Polyclonal Antibody (Antigen Affinity Purified)	50160-RP02

PLAUR / CD87 cDNA Clone

Molecule	Species	Description	Cat. No
PLAUR/CD87/u-PAR	Human	Homo sapiens PLAUR/CD87/u-PAR cDNA Clone(NM_002659.2)	HG10925-M
PLAUR/CD87/u-PAR	Mouse	Mus musculus PLAUR/CD87/u-PAR cDNA Clone	MG50160-M

PLAUR / CD87 Alternative Names

PLAUR, CD87, UPAR, URKR [Homo sapiens]

Plaur, Cd87, u-PAR, uPAR [Mus musculus]

PLAUR / CD87 Related Areas

Enzyme>>Protease & Regulator>>Serine Protease & Regulator>>PLAUR/CD87/u-PAR

Immunology>>Innate Immunity>>Coagulation>>PLAUR/CD87/u-PAR

Immunology>>Cluster of Differentiation>>Other>>PLAUR/CD87/u-PAR

Cardiovascular>>Coagulation>>PLAUR/CD87/u-PAR

PLAUR / CD87 Background

Urokinase plasminogen activator (uPA) and/or its receptor (uPAR) are essential for metastasis, and overexpression of these molecules is strongly correlated with poor prognosis in a variety of malignant tumours. uPAR and uPA levels in both resected tumor tissue and plasma are of independent prognostic significance for patient survival in several types of human cancer. This system has classically been thought to drive tumor progression by mediating directed extracellular proteolysis on the surface of migrating or invading cells, and intervening with this proteolysis by targeting uPAR has been proposed to represent a novel approach for inhibiting tumor progression. uPAR, also known as PLAUR or CD87, has been implicated in the growth, metastasis, and angiogenesis of several solid and hemotologic malignancies. uPAR is a highly glycosylated, 55-60kDa integral membrane protein linked to the plasma membrane by a glycosylphosphatidylinositol (GPI) anchor. It is part of a cell surface system that also consists of the serine protease uPA and several specific inhibitors (plasminogen activator inhibitors 1 and 2). Additionally, the analysis of CD87 (urokinase-type plasminogen activator receptor - uPAR) expression has a potential role in the diagnostic or prognostic work-up of several hematological malignancies, particularly acute leukemia and multiple myeloma.

PLAUR / CD87 Related Studies

1. Romer J, et al. (2004) The urokinase receptor as a potential target in cancer therapy. Curr Pharm Des. 10(19): 2359-76.
2. Béné MC, et al. (2004) CD87 (urokinase-type plasminogen activator receptor), function and pathology in hematological disorders: a review. Leukemia. 18(3): 394-400.
3. Pillay V, et al. (2007) The urokinase plasminogen activator receptor as a gene therapy target for cancer. Trends Biotechnol. 25(1): 33-9.
4. Mazar AP. (2008) Urokinase plasminogen activator receptor choreographs multiple ligand interactions: implications for tumor progression and therapy. Clin Cancer Res. 14(18): 5649-55.